Palvella Therapeutics, Inc.
PVLA
$23.98
-$0.45-1.84%
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 28.24% | 30.83% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 74.07% | 24.62% | |||
| Operating Income | -74.07% | -24.62% | |||
| Income Before Tax | -62.39% | -24.39% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -62.39% | -24.39% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -62.39% | -24.39% | |||
| EBIT | -74.07% | -24.62% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -59.62% | -23.05% | |||
| Normalized Basic EPS | -62.38% | -24.39% | |||
| EPS Diluted | -59.62% | -23.05% | |||
| Normalized Diluted EPS | -62.38% | -24.39% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
